Maintenance Trials
| ClinicalTrials.gov Identifier: |
NCT03793179 |
This study is currently recruiting participants.
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer.
British Columbia
BCCA-Fraser Valley Cancer Centre, Surrey
BCCA-Vancouver Cancer Centre, Vancouver
New Brunswick
Atlantic Health Sciences Corporation-Saint John Regional Hospital, Saint John
Ontario
Kingston Health Sciences Centre, Kingston
Niagara Health System-Saint Catharines General, Saint Catharines
University Health Network-Princess Margaret Hospital, Toronto
Prince Edward Island
PEI Cancer Treatment Centre-Queen Elizabeth Hospital, Charlottetown
Quebec
The Research Institute of the McGill University Health Centre (MUHC), Montreal
CHA Hopital L'Enfant-Jesus, Quebec City
| ClinicalTrials.gov Identifier: |
NCT03833154 |
This study is currently recruiting participants.
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.
Alberta
Edmonton
Ontario
London
Toronto
Quebec
Montreal
| ClinicalTrials.gov Identifier: |
NCT04931654 |
This study is currently active and recruiting participants
This study will compare the clinical activity of novel regimens (in combination or as single agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study will be conducted in two parts. Part 1 is an open-label, optional, non-randomized part based on safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to generate additional data to qualify novel regimens for the randomized study. Part 2 is a randomized, Phase II open-label part comparing the efficacy and safety of these novel regimens with SoC. Drug name mentioned as GSK4428859A and EOS884448 are interchangeable for the same compound and will be referred to as GSK4428859A/EOS884448.
Alberta
Edmonton, Alberta, Canada, T6G 1Z2
Contact: US GSK Clinical Trials Call Center 877-379-3718 [email protected]
Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 [email protected]
Principal Investigator: Quincy Chu
Ontario
Brampton, Ontario, Canada, L6R 3J7
Contact: US GSK Clinical Trials Call Center 877-379-3718 [email protected]
Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 [email protected]
Principal Investigator: Parneet Cheema
Toronto, Ontario, Canada, M5G 2M9
Contact: US GSK Clinical Trials Call Center 877-379-3718 [email protected]
Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 [email protected]
Principal Investigator: Adrian Sacher
| ClinicalTrials.gov Identifier: |
NCT01725165 |
This study is active, but not recruiting participants.
The goal of this clinical research study is to learn if surgery or radiation after chemotherapy can help to control NSCLC. The safety of this treatment will also be studied.
Ontario
London Health Sciences Centre
London, Ontario, N6A 5W9
| ClinicalTrials.gov Identifier: |
NCT02486718 |
This study is active, but not recruiting participants.
A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer.
Ontario
Etobicoke
East York
QC
Laval
| ClinicalTrials.gov Identifier: |
NCT04513925 |
This study is active, but not recruiting participants.
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
Manitoba
CancerCare Manitoba, Winnipeg
Ontario
Royal Victoria Regional Health Centre, Barrie
William Osler Health System - Brampton Civic Hospital, Brampton
Ottawa Hospital Research Institute, Ottawa
Health Sciences North, Sudbury
Quebec
Jewish General Hospital, Montreal
|
ClinicalTrials.gov Identifier:
|
NCT03703297
|
This study is currently active but not recruiting participants.
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy.
Alberta
Edmonton
Manitoba
Winnipeg
Ontario
Hamilton
London
Ottawa
Toronto
Quebec
Montreal
| ClinicalTrials.gov Identifier: |
NCT03137771 |
This study is currently suspended (Scheduled Interim Monitoring).
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Local consolidation therapy such as radiation/stereotactic body radiation or surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy and local consolidation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.
Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Site Public Contact, 780-432-8500
Principal Investigator: Brock J. Debenham
Ontario
London Regional Cancer Program
London, Ontario, Canada, N6A 4L6
Ottawa Hospital and Cancer Center-General Campus
Ottawa, Ontario, Canada, K1H 8L6
Contact: Site Public Contact, 613-761-4395
Principal Investigator: Robert M. MacRae
| ClinicalTrials.gov Identifier: |
NCT02504372 |
This study is currently active but not recruiting participants.
In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is that pembrolizumab will provide improved disease-free survival (DFS) versus placebo.
Quebec
Merck Canada
Kirkland, Quebec, Canada, H9H 4M7
Contact: Medical Information Centre/Centre d'information medicale Merck Canada Inc.,
514-428-8600/1-800-567-2594
| ClinicalTrials.gov Identifier: |
NCT04093167 |
This study is active but not recruiting participants
The purpose of stage 1 of the study is to find out if blood tests can be used to see how the cancer is responding to treatment with pembrolizumab.
British Columbia
BC Cancer - Vancouver Cancer Centre
Ontario
Juravinski Cancer Centre at Hamilton Health Sciences
Ottawa Hospital Research Institute
University Health Network